tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP

1.330USD

0.000
Horário de mercado ETCotações atrasadas em 15 min
1.96MValor de mercado
PerdaP/L TTM

60 Degrees Pharmaceuticals Inc

1.330

0.000
Mais detalhes de 60 Degrees Pharmaceuticals Inc Empresa
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Informações da empresa
Código da empresaSXTP
Nome da Empresa60 Degrees Pharmaceuticals Inc
Data de listagemJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço1025 Connecticut Avenue Nw
CidadeWASHINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal20036
Telefone12023275422
Sitehttps://60degreespharma.com/
Código da empresaSXTP
Data de listagemJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
8.82K
+131.03%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Operating Officer
Chief Operating Officer
4.54K
+22.47%
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
+0.43%
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
+0.43%
Mr. Patrick Gaynes
Mr. Patrick Gaynes
IR Contact Officer
IR Contact Officer
--
--
Dr. Ll S. Dow, Ph.D.
Dr. Ll S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
8.82K
+131.03%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Operating Officer
Chief Operating Officer
4.54K
+22.47%
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
+0.43%
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
+0.43%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 26 de jul
Atualizado em: sáb, 26 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
8.37%
Orca Capital GmbH
5.15%
Intracoastal Capital, L.L.C.
1.41%
Knight Therapeutics, Inc.
1.05%
Dow (Geoffrey S)
0.62%
Other
83.40%
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
8.37%
Orca Capital GmbH
5.15%
Intracoastal Capital, L.L.C.
1.41%
Knight Therapeutics, Inc.
1.05%
Dow (Geoffrey S)
0.62%
Other
83.40%
Tipos de investidores
Investidores
Proporção
Investment Advisor
14.04%
Corporation
2.46%
Individual Investor
1.22%
Investment Advisor/Hedge Fund
0.37%
Hedge Fund
0.05%
Other
81.86%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
28
103.36K
3.20%
+13.74K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Knight Therapeutics, Inc.
33.90K
2.3%
+14.67K
+76.26%
Sep 30, 2024
Dow (Geoffrey S)
19.97K
1.36%
+4.38K
+28.07%
Jun 09, 2025
UBS Financial Services, Inc.
16.19K
1.1%
+12.11K
+296.57%
Mar 31, 2025
Geode Capital Management, L.L.C.
11.92K
0.81%
+11.92K
--
Mar 31, 2025
Xu (Cheryl)
8.82K
0.6%
+5.00K
+131.03%
Jun 03, 2025
Miller (Tyrone)
5.27K
0.36%
--
--
Mar 27, 2025
Landon (Kristen)
4.54K
0.31%
+833.00
+22.47%
Mar 27, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Data
Tipo
Proporção
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
KeyAI